Triple-Drug Antibody-Drug Conjugate Strategy Shows Promise in Hard-to-Treat Breast Cancer
A real-world study of 87 patients suggests that combining Trop-2 antibody-drug conjugates with PD-1 inhibitors and anti-angiogenic therapy substantially improves ...
